Even though Elevidys beat Wall Street expectations, analysts expect investor focus to shift toward Sarepta's early-stage RNA drugs.
An article from
Even though Elevidys beat Wall Street expectations, analysts expect investor focus to shift toward Sarepta’s early-stage RNA drugs.
Published May 7, 2026
Sarepta shares slid on May 7, 2026 despite sales of its gene therapy Elevidys beating Wall Street projections.
Courtesy of Sarepta
Astellas treatment offers new hope to a devastated rare disease community
Are analysts too quick to gloss over Lilly's liver case?
Rezdiffra is exceeding Wall Street's expectations as the MASH market takes shape
Pfizer tops Wall Street estimates, reaffirms outlook as newer products show growth
FDA to reconsider treatment for rare cancer after its surprise rejection
Novo Nordisk's less-bad news on its Wegovy pill boosts earnings and share price
